CEO, CO-FOUNDER & BOARD MEMBER
Previously a CEO of a start up company from idea to application and from concept to a successful publicly traded company. Extensive management and financial experience. Financially lead a variety of international and public companies. Led private equity raising for public companies. Strong Involvement in M&A transactions.
PhD in Chemistry/Biophysics. Conducted research on Molecular NanoMachines at University of California, Berkeley. Over 14 years of Research and Development in Medtech companies, most recently CTO of Breast Cancer company with strong experience in bringing technologies from in vivo to human FDA/CE/CFDA studies.
SCIENTIFIC ADVISOR and CO-FOUNDER
Professor of Chemistry, Materials Science and NanoEngineering
Department of Chemistry, Rice University
Ranked one of the Top 50 most influential scientists in the world. Over 700 research publications and over 130 patent families. Co-Founder of several companies among them Dotz, Weebit, Universal Matter.
Former VP, R&D Asia, and Sr. Research Fellow, Eli Lilly ($106B Market Cap)
CEO， Tyligand Bioscience. Chairman of the BoD of BayHelix Group. 25 years’ experience in new drug discovery and development.
R&D PROJECT MANAGER
PhD in Chemistry. More than 10 years of R&D experience in cancer Nanomedicine: molecular nanomachines, gold nanoshells and light-activated therapies. Former NIH T32 Cancer Nanotech Postdoctoral Fellow at MD Anderson Cancer Center/Rice University in the laboratories of Dr. Sunil Krishnan/Prof. James Tour. Has developed the bioassays for Molecular NanoMachines disrupting cancer cells.